Cargando…

Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential

WT1(126) (RMFPNAPYL) is a human leukocyte antigen-A2 (HLA-A2)-restricted peptide derived from Wilms tumor protein 1 (WT1), which is widely expressed in a broad spectrum of leukemias, lymphomas and solid tumors. A novel T-cell-receptor (TCR)-like single-chain variable fragment (scFv) antibody specifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Q, Ahmed, M, Tassev, D V, Hasan, A, Kuo, T-Y, Guo, H-F, O'Reilly, R J, Cheung, N-K V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788467/
https://www.ncbi.nlm.nih.gov/pubmed/25987253
http://dx.doi.org/10.1038/leu.2015.125
_version_ 1782420737519255552
author Zhao, Q
Ahmed, M
Tassev, D V
Hasan, A
Kuo, T-Y
Guo, H-F
O'Reilly, R J
Cheung, N-K V
author_facet Zhao, Q
Ahmed, M
Tassev, D V
Hasan, A
Kuo, T-Y
Guo, H-F
O'Reilly, R J
Cheung, N-K V
author_sort Zhao, Q
collection PubMed
description WT1(126) (RMFPNAPYL) is a human leukocyte antigen-A2 (HLA-A2)-restricted peptide derived from Wilms tumor protein 1 (WT1), which is widely expressed in a broad spectrum of leukemias, lymphomas and solid tumors. A novel T-cell-receptor (TCR)-like single-chain variable fragment (scFv) antibody specific for the T-cell epitope consisting of the WT1/HLA-A2 complex was isolated from a human scFv phage library. This scFv was affinity-matured by mutagenesis combined with yeast display and structurally analyzed using a homology model. This monovalent scFv showed a 100-fold affinity improvement (dissociation constant (K(D))=3 nm) and exquisite specificity towards its targeted epitope or HLA-A2(+)/WT1(+) tumor cells. Bivalent scFv-huIgG1-Fc fusion protein demonstrated an even higher avidity (K(D)=2 pm) binding to the T-cell epitope and to tumor targets and was capable of mediating antibody-dependent cell-mediated cytotoxicity or tumor lysis by chimeric antigen receptor-expressing human T- or NK-92-MI-transfected cells. This antibody demonstrated specific and potent cytotoxicity in vivo towards WT1-positive leukemia xenograft that was HLA-A2 restricted. In summary, T-cell epitopes can provide novel targets for antibody-based therapeutics. By combining phage and yeast displays and scFv-Fc fusion platforms, a strategy for developing high-affinity TCR-like antibodies could be rapidly explored for potential clinical development. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/leu.2015.125) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4788467
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-47884672016-03-11 Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential Zhao, Q Ahmed, M Tassev, D V Hasan, A Kuo, T-Y Guo, H-F O'Reilly, R J Cheung, N-K V Leukemia Article WT1(126) (RMFPNAPYL) is a human leukocyte antigen-A2 (HLA-A2)-restricted peptide derived from Wilms tumor protein 1 (WT1), which is widely expressed in a broad spectrum of leukemias, lymphomas and solid tumors. A novel T-cell-receptor (TCR)-like single-chain variable fragment (scFv) antibody specific for the T-cell epitope consisting of the WT1/HLA-A2 complex was isolated from a human scFv phage library. This scFv was affinity-matured by mutagenesis combined with yeast display and structurally analyzed using a homology model. This monovalent scFv showed a 100-fold affinity improvement (dissociation constant (K(D))=3 nm) and exquisite specificity towards its targeted epitope or HLA-A2(+)/WT1(+) tumor cells. Bivalent scFv-huIgG1-Fc fusion protein demonstrated an even higher avidity (K(D)=2 pm) binding to the T-cell epitope and to tumor targets and was capable of mediating antibody-dependent cell-mediated cytotoxicity or tumor lysis by chimeric antigen receptor-expressing human T- or NK-92-MI-transfected cells. This antibody demonstrated specific and potent cytotoxicity in vivo towards WT1-positive leukemia xenograft that was HLA-A2 restricted. In summary, T-cell epitopes can provide novel targets for antibody-based therapeutics. By combining phage and yeast displays and scFv-Fc fusion platforms, a strategy for developing high-affinity TCR-like antibodies could be rapidly explored for potential clinical development. SUPPLEMENTARY INFORMATION: The online version of this article (doi:10.1038/leu.2015.125) contains supplementary material, which is available to authorized users. Nature Publishing Group UK 2015-05-19 2015 /pmc/articles/PMC4788467/ /pubmed/25987253 http://dx.doi.org/10.1038/leu.2015.125 Text en © Macmillan Publishers Limited 2015 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Zhao, Q
Ahmed, M
Tassev, D V
Hasan, A
Kuo, T-Y
Guo, H-F
O'Reilly, R J
Cheung, N-K V
Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
title Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
title_full Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
title_fullStr Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
title_full_unstemmed Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
title_short Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
title_sort affinity maturation of t-cell receptor-like antibodies for wilms tumor 1 peptide greatly enhances therapeutic potential
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788467/
https://www.ncbi.nlm.nih.gov/pubmed/25987253
http://dx.doi.org/10.1038/leu.2015.125
work_keys_str_mv AT zhaoq affinitymaturationoftcellreceptorlikeantibodiesforwilmstumor1peptidegreatlyenhancestherapeuticpotential
AT ahmedm affinitymaturationoftcellreceptorlikeantibodiesforwilmstumor1peptidegreatlyenhancestherapeuticpotential
AT tassevdv affinitymaturationoftcellreceptorlikeantibodiesforwilmstumor1peptidegreatlyenhancestherapeuticpotential
AT hasana affinitymaturationoftcellreceptorlikeantibodiesforwilmstumor1peptidegreatlyenhancestherapeuticpotential
AT kuoty affinitymaturationoftcellreceptorlikeantibodiesforwilmstumor1peptidegreatlyenhancestherapeuticpotential
AT guohf affinitymaturationoftcellreceptorlikeantibodiesforwilmstumor1peptidegreatlyenhancestherapeuticpotential
AT oreillyrj affinitymaturationoftcellreceptorlikeantibodiesforwilmstumor1peptidegreatlyenhancestherapeuticpotential
AT cheungnkv affinitymaturationoftcellreceptorlikeantibodiesforwilmstumor1peptidegreatlyenhancestherapeuticpotential